Novel drug may take on lung cancer.
Scientists now report that a novel agent bottles up this so-called epidermal growth factor receptor and stalls the growth of cancer cells in a lab dish. The strong results have led the researchers to begin testing the new drug, called HKI-272, in people with lung cancer that has proved resistant to two existing anticancer drugs that target the same receptor, reports Daniel A. Haber of Massachusetts General Hospital Cancer Center in Charlestown.--N.S.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||MICROBIOLOGY; testing HKI-272 drug for lung cancer|
|Article Type:||Brief Article|
|Date:||May 7, 2005|
|Previous Article:||Anti-inflammatories cut risk of mouth cancer.|
|Next Article:||Insights from Insects: What Bad Bugs Can Teach Us.|